Meds & supplements › Vorasidenib
Medicine · Isocitrate Dehydrogenase 1 Inhibitor
Vorasidenib
VORANIGO is indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
Drug facts
- Used for
- VORANIGO is indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation
What it is used for
VORANIGO is indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation, as detected by an FDA-approved test, following surgery including biopsy, sub-total resection, or gross total resection.
Side effects, and when to stop
The following clinically significant adverse reactions are described elsewhere in the labeling:
- Hepatotoxicity
Who should not take it
None.
Storing it
Storage
Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F to 86°F).
Cite this page
- NLM
sofidex [Internet]. Daloreum; c2026. Vorasidenib; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/vorasidenib
- APA 7th
sofidex. (2026, August 3). Vorasidenib. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/vorasidenib
- AMA 11th
Vorasidenib. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/vorasidenib
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.